Ticagrelor Tablet
Product Images NDC 77771-521

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 77771-521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Radha Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Ticagrelor Tablets 1)

A line chart comparing cumulative percentage over days from first study drug dose for ticagrelor 90 mg and clopidogrel. The solid line represents ticagrelor, and the dashed line represents clopidogrel. The chart includes patient counts at risk at various time points and an inset table summarizing event counts and KM percentages at 12 months for both drugs.*

FDA Label Image

9 (Ticagrelor Tablets 10)

A chart showing the effect of ticagrelor at various doses on the pharmacokinetics of interacting drugs, including simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, toltuamide, digoxin, and cyclosporine. The graph plots changes in Cmax and AUC relative to each interacting drug alone with recommendations for dose adjustments, primarily indicating no dose adjustment needed except a maximum simvastatin dose recommendation.*

FDA Label Image

10 (Ticagrelor Tablets 11)

A cumulative percentage line graph comparing ticagrelor 90 mg and clopidogrel over 360 days from randomization. The graph includes event rates, number at risk, and statistical data such as p-value and confidence interval for ticagrelor versus clopidogrel.*

FDA Label Image

11 (Ticagrelor Tablets 12)

A forest plot comparing the overall treatment effects and subgroup analyses between ticagrelor and clopidogrel, showing hazard ratios (HR) and 95% confidence intervals (CI) across various characteristics such as geographic region, ASA dose, treatment approach, history, age group, sex, and race. Ticagrelor is compared to clopidogrel, indicating which treatment is favored for each subgroup.*

FDA Label Image

12 (Ticagrelor Tablets 13)

A data table comparing hazard ratios (HRs) with 95% confidence intervals for ticagrelor versus clopidogrel by ASA dose in US and non-US regions. The table displays sample sizes (N), events (E), and HRs for ASA doses >=300 mg, 100-<300 mg, and <=100 mg, with a graphical forest plot adjacent illustrating the relative efficacy of ticagrelor versus clopidogrel.*

FDA Label Image

13 (Ticagrelor Tablets 14)

A Kaplan-Meier cumulative event curve showing the percentage of events over time in days from randomization for ticagrelor 90 mg, ticagrelor 60 mg, and placebo groups. The graph includes data on the number of patients at risk at various time points and a summary table with hazard ratios, confidence intervals, and p-values comparing the ticagrelor doses to placebo.*

FDA Label Image

14 (Ticagrelor Tablets 15)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals for ticagrelor versus placebo across various patient subgroups, such as age groups, sex, race, weight, BMI, geographic region, and medical history. The chart visually presents whether ticagrelor or placebo is favored in each subgroup, with HR values and event counts listed for both treatment arms.*

FDA Label Image

15 (Ticagrelor Tablets 16)

A cumulative percentage line graph comparing ticagrelor and placebo groups over months from randomization. The x-axis represents months (0 to 54), and the y-axis shows cumulative percentage (0% to 14%). Two lines display event rates: solid for ticagrelor, dashed for placebo, with event counts over total participants noted. Risk numbers for both groups are listed for each time point.*

FDA Label Image

16 (Ticagrelor Tablets 17)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) for various patient characteristics in a clinical study of ticagrelor versus placebo. The chart includes demographics, medical history, and baseline clinical factors, visually indicating whether ticagrelor or placebo is favored across subgroups.*

FDA Label Image

17 (Ticagrelor Tablets 18)

A Kaplan-Meier cumulative incidence curve comparing ticagrelor 90 mg twice daily and placebo over 34 days from randomization. The y-axis shows cumulative percentage, and the x-axis shows days. The graph includes the number at risk for each group at various time points, illustrating event rates for both treatment and placebo groups.*

FDA Label Image

18 (Ticagrelor Tablets 19)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) for various patient characteristics assessing the efficacy of ticagrelor versus placebo. The chart includes subgroups based on age, sex, race, weight, BMI, geographic region, medical history, and smoking status, illustrating ticagrelor's relative risk outcomes in these categories.*

FDA Label Image

2 (Ticagrelor Tablets 2)

A bar chart depicting the percentage of patients who had an event following coronary artery bypass graft (CABG) surgery over a series of days. The chart compares two groups labeled 'T' and 'C', showing event percentages for each day from 1 to 8 or more days. The x-axis represents the days, while the y-axis shows the percentage of patients. T and C values are also presented in a table format below the chart.*

FDA Label Image

3 (Ticagrelor Tablets 3)

A line graph comparing cumulative percentage (%) of events over months from randomization between two groups: Ticagrelor (solid line) and Placebo (dashed line). The x-axis represents months from 0 to 54, and the y-axis shows cumulative percentage from 0 to 7%. The graph includes a table of numbers at risk and shows higher event percentages for Ticagrelor. *

FDA Label Image

4 (Ticagrelor Tablets 4)

A cumulative percentage plot comparing ticagrelor 90 mg twice daily to placebo over days from randomization. The y-axis shows cumulative percentage, and the x-axis shows days from randomization. The graph displays two lines: a solid line for ticagrelor and a dashed line for placebo, with ticagrelor demonstrating higher cumulative events. At-risk population numbers are presented below the x-axis for each group.*

FDA Label Image

Abc (Ticagrelor Tablets 5)

Chemical structure of ticagrelor, a medication shown as a molecular diagram with atoms and bonds representing its chemical composition.*

FDA Label Image

5 (Ticagrelor Tablets 6)

A line graph comparing platelet inhibition activity (IPA %) over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. Ticagrelor shows a rapid and sustained increase in IPA up to about 90%, Clopidogrel shows a moderate increase peaking around 50%, and placebo remains low throughout the 8-hour period.*

FDA Label Image

Ticagrelor-tablets-60mg-60s (Ticagrelor Tablets 60mg 60s)

Label for ticagrelor tablets, 60 mg, an oral prescription drug. The label includes the proprietary name ticagrelor, strength 60 mg, package size of 60 tablets, and indicates Rx only. Manufactured by ScieGen Pharmaceuticals, Inc. and distributed by Radha Pharmaceuticals Inc. The label also contains storage instructions and a barcode.*

FDA Label Image

6 (Ticagrelor Tablets 7)

A line graph comparing percent inhibition of platelet aggregation (IPA) induced by 20µM ADP over time for ticagrelor, clopidogrel, and placebo. Ticagrelor shows the highest initial IPA, followed by clopidogrel, with placebo showing minimal effect. An inset graph shows a detailed view of IPA changes within the first 48 hours.*

FDA Label Image

7 (Ticagrelor Tablets 8)

A forest plot chart titled "Mean Effect and 90% CI" comparing the pharmacokinetic parameters Cmax and AUC of ticagrelor and AR-C124910XX across intrinsic factors like age, gender, ethnicity, renal impairment, end-stage renal disease, and mild hepatic impairment. Horizontal lines represent confidence intervals with recommendations indicating no dose adjustment needed for all factors shown.*

FDA Label Image

8 (Ticagrelor Tablets 9)

A chart showing mean effect and 90% confidence intervals for drug interactions with ticagrelor and AR-C124910XX. The x-axis represents change relative to reference, measuring pharmacokinetic parameters Cmax and AUC. Interacting drugs include CYP3A4 inhibitors, inducers, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl, with corresponding dosing and usage recommendations.*

FDA Label Image

Ticagrelor-tablets-90mg-60s (Ticagrelor Tablets 90mg 60s)

Label for Ticagrelor Tablets 90 mg by Radha Pharmaceuticals Inc. The label includes dosage strength, quantity of 60 tablets, manufacturer (ScieGen Pharmaceuticals, Inc.), distributor information, storage instructions, and a barcode. It advises dispensing the accompanying Medication Guide with each patient and states 'No Varnish' on the side.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.